Roopa Industries

Roopa Industries Net Debt / EBITDA

The Net Debt to EBITDA of Roopa Industries (530991.BO) as of Oct 30, 2026 is 0.28. In the previous year, Net Debt to EBITDA was 0.55 — a change of -49.34% (lower).

Net Debt / EBITDA

0.28

YoY

-49.34%

Last updated:

Net Debt to EBITDA of Roopa Industries is 2026 0.28 . Net Debt to EBITDA of Roopa Industries was 2025 0.55 . It decreases by -49.34% lower compared to the previous year.

The Roopa Industries Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2019
4.60 INR
Jan 1, 2020
4.20 INR
Jan 1, 2021
4.15 INR
Jan 1, 2022
2.38 INR
Jan 1, 2023
3.93 INR
Jan 1, 2024
4.71 INR
Jan 1, 2025
0.55 INR
Jan 1, 2026
0.28 INR
The Roopa Industries Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
0.28-49.34%
0.55-88.40%
4.71+19.87%
3.93+64.89%
2.38-42.59%
4.15-0.99%
4.20-8.81%
4.60-30.41%
6.61-13.57%
7.65-179.47%
-9.63-231.05%
7.34-154.14%
-13.57—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Roopa Industries Stock analysis

What does Roopa Industries do? Roopa Industries Ltd. manufactures pharmaceutical products, focusing on bulk drugs and drug intermediates. The company produces N,N-dicyclohexylcarbodiimide (DCC), Triphenyl Phosphine (TPP), 5-Cyano Phthalide, Glucosamine, and Bromine And Its Derivatives. Triphenyl Phosphine is used by manufacturers of Cephalosporin antibiotics and Statins, while Bromine And Its Derivatives serve agrochemicals, dyes, medical and veterinary products, water purification, and pesticides. Glucosamine is a key nutraceutical product. The primary buyers include pharmaceutical manufacturers, agrochemical companies, and producers of medical and veterinary compounds. The company's revenue streams come from the sale of these specialized chemical products to industries requiring bulk drugs and intermediates. Triphenyl Phosphine supports antibiotic and statin production, making it essential for pharmaceutical firms. Bromine And Its Derivatives cater to diverse sectors like agriculture, water treatment, and disinfection, with significant demand from agrochemical and medical product manufacturers. Glucosamine, as a sheet anchor product, drives sales in the nutraceutical market. Roopa Industries targets the pharmaceutical, agrochemical, and medical sectors with its product portfolio. The firm's focus on bulk drugs and intermediates positions it as a supplier to manufacturers of antibiotics, statins, and nutraceuticals. Its products are integral to the production of Cephalosporin group antibiotics, Statins, and various agrochemical applications, ensuring consistent demand from established industrial buyers. Roopa Industries is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Roopa Industries stock

Net Debt to EBITDA of Roopa Industries is 0.28 in 2026.

Net Debt to EBITDA of Roopa Industries changed from 0.55 to 0.28, representing a -49.34% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Roopa Industries since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Roopa Industries with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Roopa Industries

All Key Metrics — Roopa Industries